Valuation: Xencor, Inc.

Market Cap 1.16B 1.01B 934M 872M 1.64B 109B 1.67B 11.21B 4.35B 53.96B 4.35B 4.25B 188B P/E 2026 *
-4.17x
P/E 2027 * -4.98x
Enterprise Value 1.16B 1.01B 934M 872M 1.64B 109B 1.67B 11.21B 4.35B 53.96B 4.35B 4.25B 188B EV / Sales 2026 *
15.8x
EV / Sales 2027 * 10.5x
Free-Float
98.82%
Yield 2026 *
-
Yield 2027 * -
1 day+3.21%
1 week+14.92%
Current month+35.52%
1 month+35.52%
3 months+40.98%
6 months+6.13%
Current year+5.16%
1 week 14.28
Extreme 14.28
16.8
1 month 11.08
Extreme 11.075
16.8
Current year 10.38
Extreme 10.375
16.8
1 year 6.92
Extreme 6.92
18.69
3 years 6.92
Extreme 6.92
27.24
5 years 6.92
Extreme 6.92
43.61
10 years 6.92
Extreme 6.92
58.34
Manager TitleAgeSince
Chief Executive Officer 55 31/01/2005
Director of Finance/CFO 48 08/04/2024
Chief Tech/Sci/R&D Officer 61 30/09/2006
Director TitleAgeSince
Director/Board Member 55 31/07/1997
Director/Board Member 58 24/07/2014
Director/Board Member 72 17/03/2015
Date Insider Type Main position Quantity % Market Cap.
06-17Sell

Director

-6,843 0.0092%
06-14Sell

Director

-7,527 0.0102%
06-14Sell

Director

-5,064 0.0068%
Change 5-day change 1-year change 3-year change Capi.($)
+3.21%+14.92%+97.79%-36.24% 1.16B
+3.31%+1.93%+69.29%+129.27% 55.78B
-1.32%+16.55%+89.14%+101.41% 55.66B
-1.28%+3.17%-12.81%-13.04% 23.84B
+1.79%+8.13%+7.17%+424.70% 22.7B
+4.45%+8.43%+37.08%-29.19% 16.12B
+0.24%+5.96%+24.59%+186.97% 13.64B
+5.51%+22.37%+171.85%+333.54% 14.8B
+1.83%+4.69%+78.54%+143.84% 12.16B
-2.37%+7.60%+156.91%+160.12% 11.85B
Average +1.54%+7.44%+71.95%+140.14% 22.77B
Weighted average by Cap. +1.21%+5.09%+66.26%+144.07%

Financials

2026 *2027 *
Net sales 73.03M 63.94M 58.96M 55.09M 104M 6.91B 106M 708M 275M 3.41B 274M 268M 11.87B 110M 96.7M 89.16M 83.31M 157M 10.45B 160M 1.07B 415M 5.15B 415M 406M 17.95B
Net income -307M -269M -248M -231M -435M -29.04B -444M -2.97B -1.15B -14.31B -1.15B -1.13B -49.87B -288M -252M -232M -217M -409M -27.25B -416M -2.79B -1.08B -13.43B -1.08B -1.06B -46.8B
Net Debt - -
Logo Xencor, Inc.
Xencor, Inc. is a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases. It has more than 20 candidates engineered with its XmAb technology that are in clinical development, and multiple XmAb medicines are marketed by partners. Its XmAb engineering technology enables small changes to a protein structure that result in new mechanisms of therapeutic action. Its wholly-owned development candidates include XmAb942, XmAb819, XmAb808, and XmAb541. Candidates co-developed with partners include Plamotamab. Its clinical-stage drug candidates advanced by partners include Xaluritamig (AMG 509), ASP2138, JNJ-9401, JNJ-1493, Xpro1595, Obexelimab, and Novartis XmAb, an undisclosed antibody candidate. Its cytokine drug candidates in clinical development consist of efbalropendekin alfa (XmAb306/RG6323). Its Vudalimab is a bispecific antibody that targets PD-1 and CTLA-4.
Employees
260
Date Price Change Volume
30/06/26 US$16.11 +3.27% 1,495,864
29/06/26 US$15.60 +3.65% 749,505
26/06/26 US$15.05 +2.10% 1,981,661
25/06/26 US$14.74 +2.01% 874,739
24/06/26 US$14.45 +2.63% 825,398
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
14
Last Close Price
15.60USD
Average target price
28.50USD
Spread / Average Target
+82.69%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. XNCR Stock